CELLDEX THERAPEUTICS INC (CLDX) Stock News

USA - NASDAQ:CLDX - US15117B2025 - Common Stock

25.905 USD

-0.29 (-1.09%)

Last: 9/30/2025, 10:35:06 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CLDX Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Benzinga

5 Analysts Assess Celldex Therapeutics: What You Need To Know

13 days ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

13 days ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

21 days ago - By: Celldex Therapeutics, Inc.

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

a month ago - By: Benzinga

What Analysts Are Saying About Celldex Therapeutics Stock

a month ago - By: Stocktwits

Why Are Celldex Shares Tumbling After Hours?

21 days ago - By: Celldex Therapeutics, Inc.

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

a month ago - By: Celldex Therapeutics, Inc.

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

a month ago - By: Celldex Therapeutics, Inc.

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

2 months ago - By: Zacks Investment Research - Mentions: YMAB

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Stocktwits

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

5 months ago - By: Yahoo Finance - Mentions: UNP POOL

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

5 months ago - By: Zacks Investment Research - Mentions: EXEL

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update